• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Haemostatic Parameters in Patients with Behçet's Disease.白塞病患者的止血参数
Sultan Qaboos Univ Med J. 2014 May;14(2):e190-6. Epub 2014 Apr 7.
2
Endothelial cell activation and hypercoagulability in ocular Behçet's disease.眼部白塞病中的内皮细胞活化与高凝状态
Am J Ophthalmol. 2004 May;137(5):850-7. doi: 10.1016/j.ajo.2003.12.010.
3
Coagulation parameters and plasma total homocysteine levels in Behcet's disease.白塞病的凝血参数及血浆总同型半胱氨酸水平
Thromb Res. 2002 Apr 1;106(1):19-24. doi: 10.1016/s0049-3848(02)00085-3.
4
Plasma levels of plasminogen activator inhibitor type 1, factor VIII, prothrombin activation fragment 1+2, anticardiolipin, and antiprothrombin antibodies are risk factors for thrombosis in hemodialysis patients.纤溶酶原激活物抑制剂1型、凝血因子VIII、凝血酶原激活片段1+2、抗心磷脂抗体及抗凝血酶原抗体的血浆水平是血液透析患者发生血栓形成的危险因素。
Semin Nephrol. 2004 Sep;24(5):495-501. doi: 10.1016/j.semnephrol.2004.06.004.
5
Vascular involvement in Behçet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin.白塞病中的血管受累:与血栓形成倾向因素、凝血激活及血栓调节蛋白的关系。
Am J Med. 2002 Jan;112(1):37-43. doi: 10.1016/s0002-9343(01)01048-8.
6
Endogenous thrombin potential in Behçet's disease: relationship with thrombosis and anticoagulant therapy.白塞病中的内源性凝血酶潜力:与血栓形成及抗凝治疗的关系
Clin Exp Rheumatol. 2014 Jul-Aug;32(4 Suppl 84):S67-71. Epub 2014 Jul 17.
7
Anticoagulant and Fibrinolytic Disorders in Patients with Behçet's Disease and Recurrent Aphthous Ulcer.白塞病和复发性阿弗他溃疡患者的抗凝和纤溶异常
Chin J Physiol. 2011 Aug 31;54(4):235-40. doi: 10.4077/CJP.2011.AMM042.
8
Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behçet's disease.白塞病患者血浆血管性血友病因子、组织型纤溶酶原激活物、纤溶酶原激活物抑制剂及抗凝血酶III水平
Scand J Rheumatol. 1995;24(6):376-82. doi: 10.3109/03009749509095184.
9
Coagulation and fibrinolytic activity in Behçet's disease.白塞病中的凝血和纤溶活性。
Thromb Haemost. 1991 Sep 2;66(3):292-4.
10
Thrombophilic risk factors and homocysteine levels in Behçet's disease in eastern Spain and their association with thrombotic events.西班牙东部白塞病患者的血栓形成风险因素和同型半胱氨酸水平及其与血栓形成事件的关联
Thromb Haemost. 2006 Apr;95(4):618-24.

引用本文的文献

1
Plasma Levels of ADAMTS-13 Antigen, ADAMTS-13 Inhibitor, ADAMTS-13 Activity, and Von Willebrand Factor in Patients with Behçet's Disease.白塞病患者血浆中ADAMTS-13抗原、ADAMTS-13抑制剂、ADAMTS-13活性及血管性血友病因子水平
Mediterr J Rheumatol. 2024 Nov 7;36(1):73-78. doi: 10.31138/mjr.020524.pla. eCollection 2025 Mar.
2
Von Willebrand Factor, Factor VIII, and Other Acute Phase Reactants as Biomarkers of Inflammation and Endothelial Dysfunction in Chronic Graft-Versus-Host Disease.血管性血友病因子、因子 VIII 和其他急性期反应物作为慢性移植物抗宿主病中炎症和内皮功能障碍的生物标志物。
Front Immunol. 2021 Apr 30;12:676756. doi: 10.3389/fimmu.2021.676756. eCollection 2021.

本文引用的文献

1
Pattern and outcome of vascular involvement of Omani patients with Behcet's disease.阿曼 Behcet 病患者血管受累的模式和结局。
Rheumatol Int. 2011 Jun;31(6):731-5. doi: 10.1007/s00296-010-1363-z. Epub 2010 Feb 4.
2
EULAR recommendations for the management of Behçet disease.欧洲抗风湿病联盟(EULAR)关于白塞病管理的建议。
Ann Rheum Dis. 2008 Dec;67(12):1656-62. doi: 10.1136/ard.2007.080432. Epub 2008 Jan 31.
3
Homocysteine: an activity marker in Behçet's disease?同型半胱氨酸:白塞病的一种活性标志物?
J Dermatol Sci. 2007 Feb;45(2):121-6. doi: 10.1016/j.jdermsci.2006.11.008. Epub 2006 Dec 19.
4
Elevated FVIII and FIX level in a Behçet's disease patient with intracardiac thrombosis and pulmonary arterial aneurysms.一名患有心内血栓形成和肺动脉瘤的白塞病患者的凝血因子VIII和凝血因子IX水平升高。
Thromb Res. 2005;115(1-2):159-61. doi: 10.1016/j.thromres.2004.08.010.
5
Thrombophilic factors are not the leading cause of thrombosis in Behçet's disease.血栓形成倾向因素并非白塞病血栓形成的主要原因。
Ann Rheum Dis. 2004 Nov;63(11):1445-9. doi: 10.1136/ard.2003.014241.
6
Activated protein C levels in Behçet's disease and risk of venous thrombosis.白塞病中活化蛋白C水平与静脉血栓形成风险
Br J Haematol. 2004 Aug;126(4):550-6. doi: 10.1111/j.1365-2141.2004.05072.x.
7
Endothelial cell activation and hypercoagulability in ocular Behçet's disease.眼部白塞病中的内皮细胞活化与高凝状态
Am J Ophthalmol. 2004 May;137(5):850-7. doi: 10.1016/j.ajo.2003.12.010.
8
The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center.白塞病的长期死亡率和发病率:在一个专门中心对387例患者进行的20年随访结果调查
Medicine (Baltimore). 2003 Jan;82(1):60-76. doi: 10.1097/00005792-200301000-00006.
9
Coagulation parameters and plasma total homocysteine levels in Behcet's disease.白塞病的凝血参数及血浆总同型半胱氨酸水平
Thromb Res. 2002 Apr 1;106(1):19-24. doi: 10.1016/s0049-3848(02)00085-3.
10
Unchanged global fibrinolytic capacity despite increased factor VIIa activity in Behçet's disease: evidence of a prethrombotic state.
Rheumatol Int. 2002 Jan;21(4):137-40. doi: 10.1007/s00296-001-0143-1.

白塞病患者的止血参数

Haemostatic Parameters in Patients with Behçet's Disease.

作者信息

Alkaabi Juma K, Gravell David, Al-Haddabi Hamood, Pathare Anil

机构信息

Rheumatology Unit, Department of Medicine, Sultan Qaboos University Hospital, Muscat, Oman.

Department of Haematology, Sultan Qaboos University Hospital, Muscat, Oman.

出版信息

Sultan Qaboos Univ Med J. 2014 May;14(2):e190-6. Epub 2014 Apr 7.

PMID:24790741
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3997535/
Abstract

OBJECTIVES

This study aimed to evaluate the cause of thrombosis in Behçet's disease (BD) patients, since abnormalities in coagulation and fibrinolytic parameters have shown contradictory results.

METHODS

Haemostatic parameters were retrospectively evaluated in BD patients treated between January 2007 and January 2011 at Sultan Qaboos University Hospital, Oman. The blood samples of 35 Omani BD patients and 30 healthy controls were analysed for factor VIII:C levels, activated protein C resistance (APCR), von Willebrand factor (vWF) antigens (Ag), collagen binding and ristocetin co-factor activity (RiCoF), antithrombin (AT), protein C (chromogenic and clotting), protein S, homocysteine, tissue plasminogen activator, plasminogen activator inhibitor, plasminogen, alpha 2-antiplasmin, lupus anticoagulant and anticardiolipin and beta2-glycoprotein-1 antibodies.

RESULTS

The mean values of factor VIII:C, vWF Ag, AT and protein S were significantly higher in the patient group (P = 0.01, 0.006, 0.04 and 0.01, respectively). There was no deficiency in protein C. Screening for APCR, anticardiolipin antibodies, anti-beta2-glycoprotein-1 antibodies and lupus anticoagulant was negative and there were no differences in homocysteine levels, nor were there differences between patients with and without thrombosis. Six patients had elevated factor VIII:C levels (>150 IU/dL, P <0.02) which normalised on repeat measurements after three months.

CONCLUSION

The elevation of factors VIII:C, vWF Ag and AT most likely represent an acute phase phenomenon. In this study, thrombophilic factors did not seem to explain thrombotic tendency. Therefore, further mechanistic studies in a larger group of patients are needed to elucidate the basis for thrombosis in BD. We hypothesise that active BD causes vasculitic endothelial perturbation with dysfunction, leading to the observed increased propensity for thrombosis.

摘要

目的

鉴于凝血和纤溶参数异常呈现出相互矛盾的结果,本研究旨在评估白塞病(BD)患者血栓形成的原因。

方法

回顾性评估2007年1月至2011年1月在阿曼苏丹卡布斯大学医院接受治疗的BD患者的止血参数。对35名阿曼BD患者和30名健康对照者的血样进行分析,检测因子VIII:C水平、活化蛋白C抵抗(APCR)、血管性血友病因子(vWF)抗原(Ag)、胶原结合和瑞斯托霉素辅因子活性(RiCoF)、抗凝血酶(AT)、蛋白C(发色底物法和凝固法)、蛋白S、同型半胱氨酸、组织型纤溶酶原激活剂、纤溶酶原激活剂抑制剂、纤溶酶原、α2-抗纤溶酶、狼疮抗凝物以及抗心磷脂和β2-糖蛋白-1抗体。

结果

患者组中因子VIII:C、vWF Ag、AT和蛋白S的平均值显著更高(分别为P = 0.01、0.006、0.04和0.01)。蛋白C无缺乏情况。APCR、抗心磷脂抗体、抗β2-糖蛋白-1抗体和狼疮抗凝物的筛查均为阴性,同型半胱氨酸水平无差异,有血栓形成和无血栓形成的患者之间也无差异。6名患者的因子VIII:C水平升高(>150 IU/dL,P <0.02),三个月后重复测量时恢复正常。

结论

因子VIII:C、vWF Ag和AT的升高很可能代表一种急性期现象。在本研究中,血栓形成倾向因素似乎无法解释血栓形成趋势。因此,需要在更大规模的患者群体中进行进一步的机制研究,以阐明BD患者血栓形成的基础。我们推测,活动性BD会导致血管炎性内皮紊乱并伴有功能障碍,从而导致观察到的血栓形成倾向增加。